The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Most penetrating injuries are chest wounds and have a mortality rate (death rate) of under 10%. Penetrating chest trauma can injure vital organs such as the heart and lungs and can interfere with breathing and circulation. Lung injuries that can be caused by penetrating trauma include pulmonary laceration (a cut or tear) pulmonary contusion (a bruise), hemothorax (an accumulation of blood in the chest cavity outside of the lung), pneumothorax (an accumulation of air in the chest cavity) and hemopneumothorax (accumulation of both blood and air). Sucking chest wounds and tension pneumothorax may result. Penetrating trauma can also cause injuries to the heart and circulatory system. When the heart is punctured, it may bleed profusely into the chest cavity if the membrane around it (the pericardium) is significantly torn, or it may cause pericardial tamponade if the pericardium is not disrupted. In pericardial tamponade, blood escapes from the heart but is trapped within the pericardium, so pressure builds up between the pericardium and the heart, compressing the latter and interfering with its pumping. Fractures of the ribs commonly produce penetrating chest trauma when sharp bone ends pierce tissues.
== Overview == Scooter's Coffee uses a franchise model to establish new stores. Some locations are drive-through only and do not have sit-in dining areas. The buildings are standardized and measure 664 square feet (61.7 m2). Its coffee is produced by Harvest Roasting, which was founded alongside Scooter's Coffee. The menu includes hot and cold drinks, including coffee, tea, and smoothies; and food items, such as pastries, burritos, and sandwiches. It also has breakfast and kids menus. Its signature drink is the Caramelicious, an espresso drink with caramel sauce and whipped cream.
Military submarines use several systems to communicate with distant command centers or other ships. One is VLF (very low frequency) radio, which can reach a submarine either on the surface or submerged to a fairly shallow depth, usually less than 250 feet (76 m). ELF (extremely low frequency) can reach a submarine at greater depths, but has a very low bandwidth and is generally used to call a submerged sub to a shallower depth where VLF signals can reach. A submarine also has the option of floating a long, buoyant wire antenna to a shallower depth, allowing VLF transmissions by a deeply submerged boat. By extending a radio mast, a submarine can also use a "burst transmission" technique. A burst transmission takes only a fraction of a second, minimizing a submarine's risk of detection. To communicate with other submarines, a system known as Gertrude is used. Gertrude is basically a sonar telephone. Voice communication from one submarine is transmitted by low power speakers into the water, where it is detected by passive sonars on the receiving submarine. The range of this system is probably very short, and using it radiates sound into the water, which can be heard by the enemy. Civilian submarines can use similar, albeit less powerful systems to communicate with support ships or other submersibles in the area.
Sources: en.wikipedia.org
The American IFR (Integral Fast Reactor) can also be operated in an incineration mode, having some advantages in not accumulating the plutonium-242 isotope or the long-lived actinides, which cannot be easily burned except in a fast reactor. Also IFR fuel has a high proportion of burnable isotopes, while in CANDU an inert material is needed to dilute the fuel; this means the IFR can burn a higher fraction of its fuel before needing reprocessing. Most plutonium is produced in research reactors or plutonium production reactors called breeder reactors because they produce more plutonium than they consume fuel; in principle, such reactors make extremely efficient use of natural uranium. In practice, their construction and operation is sufficiently difficult that they are generally only used to produce plutonium. Breeder reactors are generally (but not always) fast reactors, since fast neutrons are somewhat more efficient at plutonium production. Plutonium-239 is more frequently used in nuclear weapons than uranium-235, as it is easier to obtain in quantity capable of criticality. The process of enriching uranium, i.e. increasing the ratio of 235U to 238U to weapons grade, is generally a more lengthy and costly process than the production of plutonium-239 from 238U and subsequent chemical separation.
16 June – Researchers report an fMRI study (31 May) that identifies circuitries and changes which may be crucial for consciousness in humans – or the loss and the recovery thereof in disorders of consciousness e.g. in coma patients. 17 June – Researchers report that a single gas-stove burner can raise the indoor concentrations of benzene, related to cancer risk, to more than that found in secondhand tobacco smoke. 19 June – Researchers review research on the substantial links between social isolation (HR ~1.32) and loneliness (HR ~1.14) and mortality. 21 June – The first successful transplant of a functional cryopreserved mammalian kidney is reported. The study demonstrates a "nanowarming" technique for vitrification for up-to-100 days preservation of transplant organs. 22 June – A study projects that by 2050, the worldwide number of adults with diabetes will more than double, from 529 million to over 1.3 billion. No country is expected to see a decline. 26 June Retatrutide, an experimental drug against obesity, is shown to achieve a more than 24% mean weight reduction in human adults during a Phase 2 trial. Astronomers detect, for the first time, methenium, CH3+ (and/or carbon cation, C+), basic ingredients of life as we know it, in interstellar space. 28 June Astronomers report the possible detection of a gravitational wave background (GWB) in the Universe. A study with controlling finds substantial links between reading for pleasure during childhood and later cognition.
=== Science and technology === Ghana launched a cellular mobile network in 1992. It was later connected to the Internet and introduced ADSL broadband services. Ghana was ranked 101st in the Global Innovation Index in 2025. The Ghana Space Science and Technology Centre (GSSTC) and Ghana Space Agency (GhsA) oversee space exploration and space programmes. GSSTC and GhsA worked to have a national security observational satellite launched into orbit in 2015. Ghana's annual space exploration expenditure has been 1% of its GDP, to support research in science and technology. In 2012, Ghana was elected to chair the Commission on Science and Technology for Sustainable Development in the South (Comsats); Ghana has a joint effort in space exploration with the South African National Space Agency.
Mechanotaxis refers to the directed movement of cell motility via mechanical cues (e.g., fluidic shear stress, substrate stiffness gradients, etc.). In response to fluidic shear stress, for example, cells have been shown to migrate in the direction of the fluid flow. Mechanotaxis is critical in many normal biological processes in animals, such as gastrulation, inflammation, and repair in response to a wound, as well as in mechanisms of diseases such as tumor metastasis. A subset of mechanotaxis - termed durotaxis - refers specifically to cell migration guided by gradients in substrate rigidity (i.e. stiffness). The observation that certain cell types seeded on a substrate rigidity gradient migrate up the gradient (i.e. in the direction of increasing substrate stiffness) was first reported by Lo et al. The primary method for creating rigidity gradients for cells (e.g., in biomaterials) consists of altering the degree of cross-linking in polymers to adjust substrate stiffness. Alternative substrate rigidity gradients include micropost array gradients, where the stiffness of individual microposts is increased in a single, designed direction.
Sources: en.wikipedia.org
== Overview == The aquatic inorganic carbon system is composed of the various ionic, dissolved, solid, and/or gaseous forms of carbon dioxide in water. These species include dissolved carbon dioxide, carbonic acid, bicarbonate anion, carbonate anion, calcium carbonate, magnesium carbonate, and others. The relative amounts of each species in a body of water depends on physical variables including temperature and salinity, as well as chemical variables like pH and gas partial pressure. Variables like alkalinity and dissolved (or total) inorganic carbon further define a mass and charge balance that constrains the total state of the system. Given any two of the four central inorganic carbon system parameters (pH, alkalinity, dissolved inorganic carbon, partial pressure of carbon dioxide) the remainder may be derived by solving a system of equations that adhere to the principles of chemical thermodynamics. For most of the 20th century, chemical equilibria in marine and freshwater systems were calculated according to various conventions, which led to discrepancies among laboratories' calculations and limited scientific reproducibility. Since 1998, a family of software programs called CO2SYS has been widely used. This software calculate chemical equilibria for aquatic inorganic carbon species and parameters. Their core function is to use any two of the four central inorganic carbon system parameters (pH, alkalinity, dissolved inorganic carbon, and partial pressure of carbon dioxide) to calculate various chemical properties of the system.
== Toxicity == Upon binding, the toxin is suggested to induce a prolonged sensation of severe pain, accompanied with neurogenic inflammation due to enduring TRPV1 activation. However, specific behavioural effects remain unknown. In line with the isolated toxin effect, the toxic effects of the crude venom are reported to be mainly nociceptive and inflammatory, but not lethal.
==== Production ==== Angiotensin I is converted to angiotensin II (AII) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung (but also present in endothelial cells, kidney epithelial cells, and the brain). "This conversion reduces the peptide from ten amino acids (angiotensin I) to eight amino acids (angiotensin II), with the removal of the terminal His-Leu dipeptide by ACE."
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.